Palbonix

Palbociclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women and fulvestrant in women with disease progression following endocrine therapy.

Features